Post-bypass Prophylactic IVIG in Infants and Neonates

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
HypogammaglobulinemiaCongenital Heart Disease
Interventions
DRUG

IVIG

Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.

OTHER

Placebo

If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.

Trial Locations (1)

35233

Children's of Alabama, Birmingham

All Listed Sponsors
collaborator

Grifols Biologicals, LLC

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT02043379 - Post-bypass Prophylactic IVIG in Infants and Neonates | Biotech Hunter | Biotech Hunter